FibroGen Inc. (NASDAQ:FGEN) shares traded up 2.8% on Tuesday . The stock traded as high as $22.20 and last traded at $21.89, with a volume of 360,389 shares traded. The stock had previously closed at $21.30.

Separately, Credit Suisse Group AG reaffirmed a “buy” rating on shares of FibroGen in a research note on Wednesday, May 25th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $33.25.

The company’s market capitalization is $1.36 billion. The firm has a 50-day moving average of $18.84 and a 200 day moving average of $18.41.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/fibrogen-inc-fgen-trading-2-8-higher.html

FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.36 by $0.01. FibroGen had a negative return on equity of 48.66% and a negative net margin of 61.90%. On average, equities research analysts forecast that FibroGen Inc. will post ($1.25) EPS for the current year.

In related news, CEO Thomas B. Neff sold 27,000 shares of the business’s stock in a transaction dated Wednesday, June 29th. The shares were sold at an average price of $16.02, for a total value of $432,540.00. Following the completion of the transaction, the chief executive officer now owns 3,439,764 shares of the company’s stock, valued at approximately $55,105,019.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Thomas B. Neff sold 37,798 shares of the business’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $18.38, for a total transaction of $694,727.24. Following the completion of the transaction, the chief executive officer now directly owns 3,413,255 shares of the company’s stock, valued at approximately $62,735,626.90. The disclosure for this sale can be found here. 14.90% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. HBK Investments L P purchased a new position in shares of FibroGen during the first quarter valued at $528,000. State Street Corp increased its position in shares of FibroGen by 15.1% in the first quarter. State Street Corp now owns 1,330,809 shares of the biopharmaceutical company’s stock valued at $28,335,000 after buying an additional 174,369 shares during the last quarter. Landscape Capital Management L.L.C. increased its position in shares of FibroGen by 652.2% in the first quarter. Landscape Capital Management L.L.C. now owns 99,295 shares of the biopharmaceutical company’s stock valued at $2,114,000 after buying an additional 86,095 shares during the last quarter. Palisade Capital Management LLC NJ increased its position in shares of FibroGen by 6.3% in the first quarter. Palisade Capital Management LLC NJ now owns 55,350 shares of the biopharmaceutical company’s stock valued at $1,178,000 after buying an additional 3,280 shares during the last quarter. Finally, BlackRock Fund Advisors increased its position in shares of FibroGen by 2.7% in the first quarter. BlackRock Fund Advisors now owns 1,956,290 shares of the biopharmaceutical company’s stock valued at $41,649,000 after buying an additional 51,957 shares during the last quarter. 49.82% of the stock is owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

5 Day Chart for NASDAQ:FGEN

Receive News & Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.